Skip to Content

Asfotase alfa

In the US, Asfotase alfa (asfotase alfa systemic) is a member of the drug class miscellaneous metabolic agents and is used to treat Hypophosphatasia.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A16AB13

CAS registry number (Chemical Abstracts Service)

1174277-80-5

Chemical Formula

C7108-H11008-N1968-O2206-S56

Molecular Weight

161123

Therapeutic Category

Enzyme replacement therapy

Chemical Name

tissue-nonspecific alkaline phosphatase- IgG1 fusion protein; human tissue-nonspecific isozyme alkaline phosphatase (AP-TNAP, EC=3.1.3.1) fusion protein with leucyl-lysyl-human immunoglobulin G1 Fc region {(6-15)-H-CH2-CH3 of IGHG1*03} fusion protein with (WHO)

Foreign Names

  • Asfotasum alfa (Latin)
  • Asfotase alfa (German)
  • Asfotase alfa (French)
  • Asfotasa alfa (Spanish)

Generic Names

Brand Names

  • Strensiq
    Alexion, Germany; Alexion, United States; Alexion Pharmaceuticals UK, United Kingdom
  • STRENSIQ
    Alexion, Canada

International Drug Name Search

Glossary

TermDefinition
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide